Unique IVD Parameters
BÜhlmann CORE
What makes BÜHLMANN unique in the world of diagnostics? We have asked our customers, distributors and employees. Their answers can be symbolized up in the mascot of BÜHLMANN, the Saint Bernard Dogs, as they accompany us since more than 30 years. Saint Bernard dogs are unique, reliable and independent. And so is BÜHLMANN.
Unique IVD Parameters
BÜHLMANN is focusing on five selected areas of in-vitro diagnostics: Cellular Allergy, NeuroImmunology, Inflammation, Chronobiology and Clinical Chemistry.
BÜHLMANN offered diagnostics beyond the usual: For example with its unique and patented menu of cellular allergy assays, the CAST® system (Cellular Antigen Stimulation Test), based on ELISA or flow cytometry technologies, provide results beyond conventional IgE assays. Main applications are insect venoms, food, latex, antibiotics or non-IgE mediated allergies such as drug hypersensitivities.
BÜHLMANN today is world leader in speciality diagnostics like melatonin assays or ganglioside assays, but also in niche markets like Amanitin phalloides intoxication diagnosis.
Rapidly growing today are also the BÜHLMANN Calprotectin assays, either as Calprotectin ELISA or as the first quantitative rapid test on the Quantum Blue® Reader.
BÜHLMANN is known for more than 30 years for the outstanding quality of its products, its excellent aftersales services and a worldwide availability through a network of highly qualified distributors. The company is certified according to the international standards ISO 9001:2008 and ISO 13485:2003.
Contact
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch
| Your local distributor Order About us Job opportunities |
Search
News
The recently launched EntroGen BRAF (V600E/K/D) test, that can be run on your real-time PCR instrument, is now CE-IVD marked
The EntroGen BRAF (V600E/K/D) test is a very useful tool for the detection of important mutations found in melanoma, because it detects, beside the V600E more
INFINITI KRAS-BRAF study from the Basel Institut of Pathology published in the Diagnostic Molecular Pathology journal.
New publication about the INFINITI KRAS assay in the Journal Diagn Mol Path 21/1 2012 14-23, Bihl et al. In this study from the Institute of Pathology at more
Recent publications on BÜHLMANN calprotectin assays
Three very interesting new papers have been published recently. Manz et al. describes the quality and usefulness of the BÜHLMANN calprotectin ELISA in an more
NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND
BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb more
BÜHLMANN Core | BÜHLMANN Molecular | BÜHLMANN Medical | Customer Relations | About Us |
Contact |
